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Objectives. This study sought to assess potential antiarrhyth-
mic effects of an increase in the daily oral intake of magnesium
and potassium in patients with frequent ventricular arrhythmias.
Background. Magnesium and potassium contribute essentially
to the electrical stability of the heart. Despite experimental and
clinical evidence for the antiarrhythmic properties of the two
minerals, controlled data in patients with stable ventricular
arrhythmias are lacking.
Methods. In a randomized, double-blind study, 232 patients
with frequent ventricular arrhythmias (>720 ventricular pre-
mature beats [VPBs]/24 h) confirmed at baseline and after 1
week of placebo therapy were subsequently treated over 3 weeks
with either 6 mmol of magnesium/12 mmol of potassium-DL-
hydrogenaspartate daily or placebo.
Results. Compared with placebo pretreatment, active therapy
resulted in a median reduction of VPBs by 217.4% (p 5 0.001);
the suppression rate was 2.4 times greater than that in patients
randomized to 3 weeks of placebo therapy (27.4%, p 5 0.038). The
likelihood of a >260% (predefined criterion) or >270% suppression
rate (calculated from the placebo-controlled run-in period) was
1.7 (25% vs. 15%, p 5 0.044) and 1.5 times greater in the active
than in the placebo group (20% vs. 13%, p 5 0.085), respectively.
No effect of magnesium and potassium administration was ob-
served on the incidence of repetitive and supraventricular ar-
rhythmias and clinical symptoms of the patients.
Conclusions. To our knowledge, this study is the first to provide
controlled data on the antiarrhythmic effect of oral administra-
tion of magnesium and potassium salts when directed to patients
with frequent and stable ventricular tachyarrhythmias. A 50%
increase in the recommended minimum daily dietary intake of the
two minerals for 3 weeks results in a moderate but significant
antiarrhythmic effect. However, with the given therapeutic regi-
men, repetitive tachyarrhythmias and patient symptoms remain
unchanged.
(J Am Coll Cardiol 1997;29:1028–34)
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Electrical stability of the heart is maintained by electrolyte
homeostasis. Potassium and magnesium are two of the most
important minerals contributing to the generation and regula-
tion of ion channel transport processes in myocytes and by this
are essentially involved in creating normal cellular excitability,
proper and uniform impulse propagation and regular ventric-
ular recovery. Experimental and clinical studies (1–3) have
provided increasing evidence that low plasma concentrations
of the two minerals increase the risk of induction, facilitation
or aggravation of ventricular tachyarrhythmias (VTs).
Therapeutic interventions based on this concept have pri-
marily been directed at the prevention of electrolyte depletion.
More recently, the administration of magnesium salts in par-
ticular has gathered increasing interest due to its safety profile,
potential effects on preserving myocardial function and potent
antiarrhythmic properties. In most small, but not all larger,
studies (4), the administration of magnesium salts in patients
with cardiac arrhythmias resulting from chronic heart failure
(5–7) or an acute ischemic syndrome (8–10) during perioper-
ative coronary bypass graft surgery was found to be effective in
reducing tachyarrhythmic complications.
The concept of preserving electrical stability by a positive
magnesium and potassium balance is attractive because of its
simplicity, cost-effectiveness and safety. However, only very
few data and no controlled studies exist to prove any antiar-
rhythmic effect of the two minerals in patients with frequent
VTs under stable conditions. Although this group of patients
had usually not been directed to antiarrhythmic treatment in
the mid-1990s, the proven antiarrhythmic effects of magnesium
and potassium would provide a safe alternative to the present
problems with class I antiarrhythmic agents. If proven effica-
cious, potassium and magnesium might also be used as adjunctive
treatment in patients receiving antiarrhythmic drug medication.
The present double-blind, randomized, placebo-controlled
study was aimed at a large series of consecutive patients
presenting with frequent and stable VTs to assess the potential
From the Abteilung fu¨r Kardiologie, Innere Medizin III, Universita¨tsklinik
Freiburg, Freiburg; and *Abteilung fu¨r Kardiologie, Universita¨tskrankenhaus
Eppendorf, Hamburg, Germany. †A complete list of the Magnesium in Cardiac
Arrhythmias (MAGICA) Investigators appears in the Appendix. This study was
supported by Trommsdorff GmbH and Company, Alsdorf, Germany and Hexal
AG, Holzkirchen, Germany.
Manuscript received June 3, 1996; revised manuscript received July 19, 1996,
accepted December 19, 1996.
Address for correspondence: Dr. Manfred Zehender, Innere Medizin III,
Universita¨tsklinik Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany.
JACC Vol. 29, No. 5
April 1997:1028–34
1028
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00053-3
antiarrhythmic benefit of increasing the daily recommended
minimal dietary intake of magnesium and potassium by 50%
over a 3-week treatment period.
Methods
Patients. From October 1991 to September 1994, 307
consecutive patients who presented with frequent VPBs were
enrolled in the study at 20 European cardiology centers. The
study protocol was approved by the Institutional Review Board
of the University of Freiburg. All participants gave written
informed consent before enrollment in the study.
Inclusion criteria for the study were 1) presence of frequent
VPB’s (.720 ventricular premature beats [VPBs]/24 h during
baseline 24-h Holter recording); 2) confirmation of VPB
frequency after 1 week of placebo therapy (analysis A).
Patients without the second criterion were also randomized
and treated but were only considered for a secondary analysis
conducted in all patients without regard to arrhythmia vari-
ability (analysis B).
Patients had to be 18 to 75 years old and have a left
ventricular ejection fraction .25% as well as potassium (range
3.5 to 5.5 mmol/liter) and magnesium plasma levels (0.75 to
1.25 mmol/liter) within the normal range. Exclusion criteria
(alone or in combination) included the presence of malignant
ventricular arrhythmias (.6 consecutive beats .120/min; his-
tory of sustained VT/ventricular fibrillation), atrial fibrillation,
evidence or history of important renal (serum creatinine
concentration .120 mmol/liter) or liver impairment, thyroid
malfunction, New York Heart Association functional class IV,
antiarrhythmic pretreatment, angiotensin-converting enzyme
inhibitors or potassium-sparing or potassium-depleting di-
uretic drugs given ,5 days before the study. Oral medication
was optimized before entering the runin phase of the study and
was kept constant throughout the 4-week study period. Of the
232 patients included in analysis A, the use of aspirin (44
patients), nitrates (39 patients), antihypertensive drugs (25
patients), digitalis (16), calcium channel blocking agents (10
patients) and diuretic drugs (5 patients) was not different in the
active and placebo groups; cardiovascular medication was
changed during the study in only 4 patients.
Study design. Complete history, followed by physical ex-
amination and an extensive diagnostic workup, was taken in all
patients qualifying for the study. Patients then entered the
placebo-controlled 1-week run-in period. At day 7, all patients
had repeat 24-h Holter monitoring and were reassessed by
means of a standardized questionnaire for the presence of
clinical symptoms possibly related to the clinical arrhythmia.
Patients were then randomized to 3 weeks of either active
or placebo treatment. In the active treatment group, daily
oral dosing consisted of 2.163 mg of magnesium-DL-
hydrogenaspartate (6 mmol magnesium) and 2.162 mg of
potassium-DL-hydrogenaspartate (12 mmol potassium) daily.
The dose was chosen to increase the recommended minimal
daily dietary intake of magnesium (12 to 15 mmol) and
potassium (20 to 30 mmol) by ;50% in addition to usual diet
(3).
After 21 days of active or placebo treatment, 24-h Holter
registration, plasma levels of magnesium/potassium, laboratory
chemistry and 12-lead surface electrocardiogram (ECG) were
repeated. Clinical symptoms of the patients were assessed by
repeating the baseline questionnaire (10 items to describe the
clinical symptoms, from 0 5 no complaints to 5 5 very severe
complaints). In addition, the Clinical Global Impression Scale
was used by the physician to determine overall benefit of
therapy.
All 24-h Holter recordings were assessed by amplitude-
modulated systems and analyzed centrally within 48 h at the
University Hospital Freiburg using a Marquette Laser SXP0
system. Supraventricular and ventricular arrhythmias were
identified and interpreted by a physician. Representative trac-
ings were reviewed and interpreted as 1) VPBs; 2) multiform
VPBs; 3) ventricular pairs (2 repetitive VPBs); and 4) ventric-
ular salvos ($3 repetitive VPBs). Holter recordings with an
analyzable registration time ,22 h were repeated.
Comparison of drug response in the two study groups was
based on the Holter recording obtained immediately before
randomization and after 3 weeks of active or placebo treat-
ment (considered for analysis A: patients with .720 VPBs/24 h
during two 24-h Holter recordings separated by 1 week of
placebo medication; analysis B: patients with .720 VPBs/24 h
during baseline 24-h Holter recording). The frequency of
VPBs was the only major end point; repetitive arrhythmia was
not considered a relevant end point because of the low
frequency and higher spontaneous variability of this type of
arrhythmia. Two response criteria for suppression of VPBs
were used. One criterion was empirically predefined by the
investigator group (reduction rate of VPBs .60%, criterion 1).
A second reduction criterion was calculated on the basis of the
spontaneous arrhythmia variability in our particular patient
cohort as assessed during the initial Holter recordings and
those done during placebo treatment. Regression analysis was
used to determine the one-tailed 95% confidence intervals of
spontaneous variability in the examined patient cohort by
comparing the frequency of VPBs at baseline and after 1 week
of placebo therapy (12,13). The calculated minimal suppres-
sion rate was 70.2% (5% significance level, criterion 2).
Because of the low incidence and high spontaneous variability
of repetitive arrhythmias, no reduction criterion was pre-
defined or calculated.
To improve visualization of the antiarrhythmic effects of the
two minerals, a previously described (14) graphic display was
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
VPB 5 ventricular premature beat
VT 5 ventricular tachyarrhythmia
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chosen that is more sensitive to smaller but, over the total
patient cohort, constant changes in the arrhythmia frequency.
All blood samples for measuring magnesium and potassium
plasma levels were obtained under similar, standardized condi-
tions. Blood samples were allowed to clot and then centrifuged at
4°C. The serum was stored at 270°C until it could be centrally
analyzed. Serum levels of magnesium and potassium were deter-
mined in duplicate by spectrophotometric measurements.
Statistical analysis. Calculations of sample size were ob-
tained after 200 patients had completed the runin placebo
period and indicated that a total of 300 patients were required
to prove the hypothesis that active treatment would be effective
in reducing VPBs, with a significance level of 0.05 and a power
of 0.80.
Data analysis considered patients with .720 VPBs/24 h
before and after 1-week of placebo treatment (analysis A), as
well as all patients regardless of low or high spontaneous
arrhythmia variability (analysis B). Statistical analysis was
based on regression analysis according to previous recommen-
dations by Andresen (12) and Sami (13) and showed a minimal
suppression rate of 70.2% (one-tailed 95% confidence inter-
val). The antiarrhythmic effect of active treatment was assessed
by 1) comparing the effect of 1 week of placebo treatment
versus 3 weeks of magnesium/potassium treatment and 1
versus 3 weeks of placebo therapy (two-tailed Wilcoxon test,
two-tailed Mann-Whitney U test); 2) the incidence of respond-
ers (VPB reduction .60% and .70%) after 3 weeks of
placebo or active treatment (linear regression analysis); and 3)
comparison of 3 weeks of randomized placebo or active
treatment (two-tailed Mann-Whitney U test). Results are given
as median value (25, 75 quartiles), except for data showing a
normal distribution (mean value 6 SD).
Results
Patients. Of 307 consecutive patients entering the placebo
period, 232 patients (76%) presented with .720 VPBs/24-h
registration period before and after 1 week of placebo therapy
and were considered for inclusion in analysis A. Clinical and
arrhythmia data were not different for patients randomized to
active or placebo therapy (Table 1).
Ventricular and supraventricular tachyarrhythmias. In
patients with a stable arrhythmia frequency, magnesium and
potassium administration resulted in a median reduction of
daily VPB rate from 7,651 to 4,421 (median reduction
217.4%) compared with 7,485 to 5,578 VPBs/24 h (27.4%) in
the placebo group (p 5 0.038) (Table 2). The antiarrhythmic
effect of magnesium/potassium administration was observed
Table 1. Baseline Characteristics of 232 Patients Randomized to
Placebo Therapy or Treatment With Oral Magnesium and
Potassium (analysis A)
Active Therapy
(n 5 120)
Placebo Therapy
(n 5 112)
Clinical characteristics
Age (yr) 54.1 6 13.8 56.9 6 12.8
Range 20–75 20–75
Men/women 72/48 66/46
SBP (mm Hg) 133 6 16 133 6 17
DBP (mm Hg) 82 6 9 81 6 10
HR (beats/min) 75 6 12 75 6 9
CAD 35 32
Hx of infarction 19 23
Other organic CHD 36 32
No organic CHD 49 48
Laboratory chemistry (median)
Mg21 (mmol/liter) 0.85 0.84
K1 (mmol/liter) 4.65 4.49
Ca21 (mmol/liter) 2.41 2.39
Na1 (mmol/liter) 109 109
24-h Holter monitoring (median)
VPBs/24 h 7,651 7,485
.100/h (% of pts) 74 76
.200/h (% of pts) 59 62
.500/h (% of pts) 30 31
Ventricular pairs/salvos (no.) 19 23
SVPBs/24 h (median) 43 63
No. of pts 120 112
Data presented are mean value 6 SD or number of patients (pts), unless
otherwise indicated. CAD 5 coronary artery disease; CHD 5 coronary heart
disease; DBP 5 diastolic blood pressure; SBP 5 systolic blood pressure;
SVPBs 5 supraventricular premature beats; VPBs 5 ventricular premature beats.
Table 2. Antiarrhythmic Response to 3 Weeks of Oral Placebo and
Magnesium/Potassium Therapy
Active Therapy Placebo Therapy p Value
Analysis A n 5 120 n 5 112
VPB reduction
Median 217.4% 27.4% 0.038*
(25, 75 quartiles) (261%, 124%) (246%, 143%)
$60% 29 (25%) 16 (15%) 0.044†
$70%‡ 24 (20%) 14 (13%) 0.085†
VP/VT reduction
Median 242.9% 246.0% 0.604*
(25, 75 quartiles) (286%, 169%) (285%, 151%)
$90% 24 (24%) 21 (23%) 0.460†
SVPB reduction
Median 25.2% 220.3% 0.292†
(25, 75 quartiles) (265%, 1221%) (282%, 1200%)
Analysis B n 5 157 n 5 150
VPB reduction
Median 212.2% 12.2% 0.053*
(25, 75 quartiles) (262%, 137%) (243%, 169%)
$60% 40 (25%) 21 (14%) 0.008†
$70%‡ 32 (21%) 18 (12%) 0.032†
VP/VT reduction
Median 233.3% 233.3% 0.960*
(25, 75 quartiles) (284%, 188%) (290%, 167%)
$90% 29 (23%) 31 (25%) 0.721†
SVPB reduction
Median 211.8% 225.3% 0.180*
(25, 75 quartiles) (270%, 1170%) (283%, 1122%)
*Two-tailed Mann-Whitney U test. †One-tailed Fisher test. ‡Calculated by
linear regression analysis (12,13). Data presented are median (25, 75th quartiles)
or number (%) of patients. VP/VT 5 ventricular pairs/ventricular tachyarrhyth-
mia; other abbreviations as in Table 1.
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when 1 week of placebo and 3 weeks of active treatment (p ,
0.001) (Fig. 1, top) was compared with 1 and 3 weeks of
placebo treatment (p 5 0.97) (Fig. 1, bottom), as well as when
only the two randomized treatment periods (placebo vs. active
treatment for 3 weeks) were compared (Fig. 2). The graphic
display also allows easy recognition of the proportion of
patients in the two groups with a .60% or a .70% reduction
and patients with any increase or a .100% increase in
arrhythmia frequency.
Using the predefined (.60%) and calculated (.70%) VPB
suppression criteria in patients with stable arrhythmia fre-
quency, active treatment resulted in a 1.7 (25% vs. 15%, p 5
0.044) and 1.5 times (20% vs. 13%, p 5 0.085) higher response
rate than placebo treatment (Table 2). Antiarrhythmic effects
of magnesium/potassium administration were not predictable
by clinical variables, except for the presence or absence of a
history of myocardial infarction (251% vs. 28% in the placebo
group, p , 0.05).
Repetitive arrhythmias present at randomization in 99
(active group) and 93 patients (placebo group) were similar in
response to active or placebo therapy (51 vs. 26 episodes/24 h
[249%]; 37 vs. 20 episodes/24 h [246%], respectively) (Table
2). Lown class decreased by $1 class in 22 (active group) and
18 (placebo group) patients, respectively. Similarly, supraven-
tricular arrhythmias remained unchanged when magnesium/
potassium (median VPBs/24 h [25, 75 quartiles]: 43 [10, 316]
Figure 1. Cumulative number of
patients (Pts) is shown for any
given reduction or increase in the
rate of VPBs when baseline 24-h
Holter recording was compared
with that during placebo or active
treatment, or both (data are based
on analysis A). Top panel, Re-
sponse of ventricular arrhythmias
after 1 week of placebo (black
curve) and after 3 weeks of active
treatment with magnesium and po-
tassium (red curve). Comparison
was to 48-h Holter monitoring at
baseline. The leftward shift indi-
cates a significant antiarrhythmic
effect of active treatment. Bottom
panel, Response of ventricular ar-
rhythmias after 1 week of placebo
(black curve) and after 3 weeks of
placebo (blue curve). Comparison
was to 48-h Holter monitoring at
baseline. Differences were not sig-
nificant.
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vs. 61 [20, 275], p 5 NS) and placebo therapy were compared
(63 [12, 185] vs. 41 [8, 177], p 5 NS).
Plasma level of magnesium and potassium. Three weeks of
treatment resulted in no significant change in serum levels of
magnesium (active treatment: 0.85 6 0.03 vs. 0.88 6 0.04
mmol/liter; placebo treatment: 0.87 6 0.02 vs. 0.89 6 0.03
mmol/liter) or potassium (4.5 6 0.2 vs. 4.6 6 0.2 mmol/liter;
4.4 6 0.2 vs. 4.6 6 0.2 mmol/liter).
In the active treatment group, linear regression analysis
failed to detect any positive correlation between the change in
plasma concentration of magnesium (r 5 0.32) or potassium
(r 5 0.36) and VPB frequency.
Side effects, clinical symptoms and Global Clinical Impres-
sion Score. Side effects were reported by 20 patients (20%) in
the active treatment group (gastrointestinal symptoms in 18),
and by 17 (15%, p 5 NS) in the placebo group (gastrointestinal
symptoms in 15). Drug treatment was stopped because of side
effects in four and two patients, respectively.
Clinical symptoms potentially related to ventricular ar-
rhythmias were found to be not different for the two study
groups (Fig. 3). The Global Clinical Impression Score as
determined by the treating physician also demonstrated no
difference between the two study groups (excellent response:
3.5 vs. 5.6% of patients; moderate response: 19.6 vs. 21.0%; no
Figure 2. Cumulative number of patients (Pts) are
shown for any given reduction or increase in the rate
of VPBs when patients were randomly treated for 3
weeks by either magnesium and potassium (red
curve) or placebo (blue curve). The area between the
two curves marks the difference between the two
groups and indicates the antiarrhythmic effect of
active treatment (data are based on analysis A).
Figure 3. Severity of 10 clinical symptoms at
baseline (open circles), after 1-week run-in
placebo period (squares) and after 3 weeks of
treatment (solid circles) in the magnesium/
potassium (left panel) and placebo groups
(right panel). Severity of symptoms was de-
scribed by a scale from 0 (no complaints) to 5
(very severe complaints). Data shown are mean
values and are not different between the two
patient groups.
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recognizable response: 76.8 vs. 73.1%). Systolic and dia-
stolic blood pressure, heart rate and all ECG variables (PQ,
QRS, QT intervals) were unaffected by active or placebo
treatment.
Analysis of all patients independent of the presence of low
or high arrhythmia variability (analysis B). When the analysis
was based on all 307 patients with .720 VPBs/24 h during
baseline 24-h Holter recording, the arrhythmia suppression
rate was 212.2% in the active group and 12.2% in the placebo
group (p 5 0.049). Similar to analysis A, the responder rate to
both the predefined (.60% reduction of VPB, p 5 0.008) and
calculated VPB suppression criterion (.70%, p 5 0.032) were
found to be significant (Table 2).
Discussion
The concept of preserving and improving the electrical
stability of the heart by increasing the daily intake of magne-
sium and potassium salts has generated controversy in recent
years. Experimental evidence and encouraging clinical data
(5–10) stressing some antiarrhythmic effects of the two miner-
als are contrasted by a lack of controlled studies.
Antiarrhythmic effects of increased intake of magnesium
and potassium in patients with stable, frequent ventricular
arrhythmias. In a double-blind, randomized, placebo-
controlled study, 307 patients with frequent ventricular ar-
rhythmias were treated for 3 weeks by placebo or magnesium
and potassium, to increase the daily recommended minimal
dietary allowance of the two minerals by 50%.
Primary data analysis was based on those 232 patients who
presented with low spontaneous arrhythmia variability (.720
VPBs/24 h before and after 1 week placebo treatment, mean
frequency .300 VPBs/h). Secondary analysis included all 307
patients with .720 VPBs/24 h at baseline, independent from
the observed spontaneous arrhythmia variability. In patients
with stable ventricular arrhythmias, oral magnesium and po-
tassium administration resulted in a significant reduction of
arrhythmia frequency. This effect was manifest when 3-week
magnesium and potassium therapy was compared with the
1-week placebo runin period, as well as when comparison was
made only between the two randomized 3-week active or
placebo treatment periods. The predefined $60% suppression
criterion (selected to be proved an antiarrhythmic effect) and
the calculated $70% suppression criteria (logistic regression
analysis) were met by 25% and 20% of patients after oral
magnesium and potassium administration compared with 15%
and 13% of patients in the randomized placebo group. Com-
parison of the two 3-week treatment periods demonstrated a
2.4 times greater reduction rate after magnesium/potassium
than after placebo administration. The antiarrhythmic re-
sponse to magnesium and potassium was also significant when
all patients were analyzed independent of their spontaneous
arrhythmia variability. There are no other controlled data
that can be compared with the present study; uncontrolled
studies published in the late 1980s are well in line with our
findings (3).
Of all clinical variables analyzed, none were predictive of
drug-induced arrhythmia suppression, except for the presence
of a history of myocardial infarction. Plasma concentration of
the two minerals was found to be unaffected after 3 weeks of
active treatment, and there was no correlation between
changes in measured plasma concentration and the response of
ventricular arrhythmias during drug therapy. Neither finding
was unexpected because only 1% to 2% of total body store of
the two minerals is in the extracellular fluid (3,11).
Clinical symptoms present at the time of randomization
showed a significant improvement during drug treatment, but
this effect was not different between active and placebo med-
ication. In light of previous uncontrolled observations report-
ing an improvement in clinical symptoms after magnesium (3),
these data clearly emphasize the importance of a controlled
study design.
Limitations of the study. All data analyses must be inter-
preted in the light of the dosage and duration of magnesium/
potassium administration used in the present study. It is not
expected that any antiarrhythmic effect of magnesium and
potassium administration will be similar to that observed with
potent class I antiarrhythmic agents, which are now known to
cause significant side effects in some groups of patients (15,16).
With decreasing antiarrhythmic potency of the drug it becomes
more difficult to prove any positive or negative drug effect. A
controlled study design, placebo-controlled verification of ar-
rhythmia frequency and the use of different statistical tests
cannot completely exclude the influence of spontaneous ar-
rhythmia variability; however, they are very helpful in minimiz-
ing this influence.
Conclusions. To our knowledge, the present study is the
first to provide controlled data on the antiarrhythmic effects of
oral administration of magnesium and potassium salts in
patients with frequent ventricular tachyarrhythmias. An in-
crease of 50% in the daily intake of magnesium and potassium
salts for 3 weeks results in a moderate but significant antiar-
rhythmic effect. Although the likelihood of a 60% reduction of
VPBs is increased from every seventh to every fourth patient,
no significant effect of this therapeutic regimen on repetitive
ventricular tachyarrhythmias or on clinical symptoms was
observed.
The present study should not be considered an argument
for treating patients with nonmalignant ventricular tachyar-
rhythmias. In addition, it is uncertain whether any suppression
of Holter-documented ventricular arrhythmias will translate
into any clinical benefit. However, in light of its simplicity,
cost-effectiveness and safety, increasing the daily intake of
magnesium and potassium salts may provide another first-line
option for treating patients with frequent but not life-
threatening ventricular tachyarrhythmias.
We thank B. Balzer, MS for help in the organization and performance of the
MAGICA study.
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Appendix
Participating Investigators and Institutions for the
MAGICA Study
Prof. Dr. G. Bachour, Cardiological Practice, Ahlen (Germany); Dr. C. P.
Billing, Cardiological Practice, Essen (Germany); Prof. Dr. W. Enenkel, Kran-
kenhaus der Stadt Wien, Vienna (Austria); Dr. J. Gadow/Dr. J. Wunderlich,
Cardiological Practice, Berlin (Germany); Dr. F. Gulic, Allgemeines Kranken-
haus, Maribor (Slovenia); Dr. F. K. Hagel, Cardiological Practice, Nu¨rnberg
(Germany); Dr. R. Ha¨ge, Cardiological Practice, Dillingen (Germany); Dr. D.
Hu¨wel, Cardiological Practice, Dillingen (Germany); Prof. Dr. W. Klein, Ambu-
latory Practice for Long-Term ECG, Graz (Austria); Prof. Dr. E. Knapp,
Universita¨tsklinikum, Innsbruck (Austria); Dr. W. Kotulla, Cardiological Prac-
tice, Waldkirch (Germany); Prim. Prof. Dr. G. Ma¨hr, Landeskrankenhaus,
Feldkirch, (Austria); Prof. Dr. T. Meinertz, Universita¨tsklinik Eppendorf, Ham-
burg (Germany); Dr. G. Prager, Cardiological Practice, Regensburg (Germany);
Dr. H. Petri, Cardiological Practice, Hamburg (Germany); Prof. Dr. P. Rakovec,
University Medical Centre, Ljubljana (Slovenia); Prim. Prof. Dr. S. Sailer,
Landeskrankenanstalten, Salzburg (Austria); Prof. Dr. H. E. Schro¨der, Med.
Akademie, Dresden (Germany); Dr. F. Skrabl-Mocnik, Bolnica Celje, Celje
(Slovenia); Prim. Prof. Dr. K. Steinbach, Wilhelminenspital, Vienna (Austria);
Dr. R. Wolf, Herzkreislaufklinik, Bad Bevensen (Germany); PD Dr. M. Ze-
hender, Universita¨tsklinikum, Freiburg (Germany); Dr. A. Zemva, Klinicni
Center, Ljubljana (Slovenia).
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